Oxford Brain Diagnostics Ltd
Ged Ridgway is a highly experienced professional in the field of biomedical imaging and neuroscience, currently serving as the Chief Scientific Officer at Oxford Brain Diagnostics Ltd since January 2021. Previously, Ridgway held the position of Head of Imaging Science and later Biomedical Imaging Scientist at Perspectum Diagnostics Ltd from May 2017 to January 2021. Contributions as a Research Fellow at the Oxford Centre for Functional MRI of the Brain involved a Medical Research Council Fellowship focused on Alzheimer's disease. Furthermore, Ridgway has collaborated extensively with prestigious institutions such as the UCL Institute of Neurology and the Wellcome Trust Centre for Neuroimaging. Academic qualifications include a PhD in Medical Image Computing from UCL and a combined BA and MEng in Engineering from the University of Cambridge.
Oxford Brain Diagnostics Ltd
Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.